

Supplementary Table 1: Univariable analysis in the group of 3RDV treated patients depending on the primary outcome of hospitalization at 30 days.

	N (%) or mean \pm SD or median [IQR 25, 75]		p
	No hospitalization (345)	Hospitalization (10)	
Age (years)	59.9 \pm 17.6	70.4 \pm 13.9	0.061
Male gender	190 (55.1)	7 (70)	0.522
Medical history			
COPD/asthma	22 (6.4)	0 (0)	1
Hypertension	133 (38.6)	6 (60)	0.198
CAD	37 (10.7)	1 (10)	1
CHF	17 (4.9)	0 (0)	1
CKD	132 (38.3)	3 (30)	0.748
Hematological malignancy	51 (14.8)	3 (30)	0.183
Solid organ malignancy	18 (5.2)	1 (10)	0.427
Diabetes mellitus	79 (22.9)	2 (20)	1
Liver disease	12 (3.5)	0 (0)	1
Autoimmune disease	35 (10.1)	2 (20)	0.280
Immunosuppressed	207 (60)	8 (80)	0.326
CCI	4 [3, 6]	4.5 [4, 7]	0.215
Days till treatment	1 [0, 2]	0 [0, 2]	0.993
Vaccination			0.270
None	40 (11.6)	3 (30)	
1 dose	8 (2.3)	0 (0)	
2 doses	39 (11.3)	1 (10)	
3 doses	155 (45.1)	6 (60)	
4 doses	84 (24.4)	0 (0)	
5 doses	18 (5.3)	0 (0)	

3RDV: 3-day remdesivir regimen, SD: standard deviation, IQR: Interquartile range, COPD: chronic obstructive pulmonary disease, CAD: coronary artery disease, CHF: congestive heart failure, CKD: chronic kidney disease, CCI: Charlson comorbidity index

Supplementary Table 2: Univariable analysis in the group of NMV/r treated patients depending on the primary outcome of disease hospitalization at 30 days.

	N (%) or mean \pm SD or median [IQR 25, 75]		p
	No hospitalization (160)	Hospitalization (5)	
Age (years)	65 \pm 16	70.6 \pm 14.5	0.442
Male gender	96 (60)	4 (80)	0.649
Medical history			
COPD/asthma	22 (13.8)	0 (0)	1
Hypertension	78 (48.8)	4 (80)	0.210
CAD	10 (6.3)	2 (40)	0.043
CHF	10 (6.3)	1 (20)	0.295
CKD	0 (0)	1 (20)	0.03
Hematological malignancy	60 (37.5)	1 (20)	0.652
Solid organ malignancy	14 (8.8)	0 (0)	1
Diabetes mellitus	42 (26.3)	1 (20)	1
Liver disease	4 (2.5)	0 (0)	1
Autoimmune disease	13 (8.1)	0 (0)	1
Immunosuppressed	75 (46.9)	2 (40)	1
CCI	4 [2, 5]	5 [3, 6]	0.111
Days till treatment	1 [0, 2]	1 [0, 2]	0.909
Vaccination			0.022
None	16 (10)	1 (20)	
1 dose	1 (0.6)	0 (0)	
2 doses	7 (4.4)	2 (40)	
3 doses	81 (50.6)	1 (20)	
4 doses	42 (26.3)	1 (20)	
5 doses	13 (8.1)	0 (0)	

NMV/r: nirmatrelvir/ritonavir regimen, SD: standard deviation, IQR: Interquartile range, COPD: chronic obstructive pulmonary disease, CAD: coronary artery disease, CHF: congestive heart failure, CKD: chronic kidney disease, CCI: Charlson comorbidity index